Targeted inhibition of AKT in pancreatic cancer

Tawnya L. Bowles, Colin Parsons, Diego J. Muilenburg, Richard J Bold

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The understanding of the barriers to effective treatment of cancer is rapidly expanding. As the molecular pathways of apoptosis become better understood, the mechanisms by which cancer cells evade the apoptotic effect of standard chemotherapeutic agents are revealed. Protein kinase B/AKT mediates a potent survival/anti-apoptotic signal when activated; many cancers have been observed to harbor constitutive activation. The mechanism of constitutive activation of AKT in cancer is not usually due to mutation or amplification of the gene, but through activation of upstream signaling events. Extensive preliminary data has shown that inhibition of AKT restores apoptotic sensitivity in various cancers to diverse chemotherapeutic agents, yet the optimal mechanism of inhibition of AKT has yet to be clearly defined. Pancreatic cancer is one of the most difficult to treat given its extreme resistance to the cytotoxic effect of traditional therapy; investigations into therapies to restore apoptotic sensitivity have identified AKT as a potenial target for inhibition. The evolving targeted inhibition of AKT, whether directly or indirectly, is an active area of research with tremendous potential in cancer therapy, and pancreatic cancer specifically, and this field of research is discussed in the current review.

Original languageEnglish (US)
Pages (from-to)288-295
Number of pages8
JournalCurrent Cancer Therapy Reviews
Volume5
Issue number4
DOIs
StatePublished - 2009

Fingerprint

Pancreatic Neoplasms
Neoplasms
Proto-Oncogene Proteins c-akt
Research
Transcriptional Activation
Therapeutics
Apoptosis
Mutation

Keywords

  • Akt
  • Apoptosis
  • Autophagy
  • NF-κB
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Molecular Medicine

Cite this

Targeted inhibition of AKT in pancreatic cancer. / Bowles, Tawnya L.; Parsons, Colin; Muilenburg, Diego J.; Bold, Richard J.

In: Current Cancer Therapy Reviews, Vol. 5, No. 4, 2009, p. 288-295.

Research output: Contribution to journalArticle

Bowles, Tawnya L. ; Parsons, Colin ; Muilenburg, Diego J. ; Bold, Richard J. / Targeted inhibition of AKT in pancreatic cancer. In: Current Cancer Therapy Reviews. 2009 ; Vol. 5, No. 4. pp. 288-295.
@article{19dc28b3bbb245d4bd5c5d34553ca063,
title = "Targeted inhibition of AKT in pancreatic cancer",
abstract = "The understanding of the barriers to effective treatment of cancer is rapidly expanding. As the molecular pathways of apoptosis become better understood, the mechanisms by which cancer cells evade the apoptotic effect of standard chemotherapeutic agents are revealed. Protein kinase B/AKT mediates a potent survival/anti-apoptotic signal when activated; many cancers have been observed to harbor constitutive activation. The mechanism of constitutive activation of AKT in cancer is not usually due to mutation or amplification of the gene, but through activation of upstream signaling events. Extensive preliminary data has shown that inhibition of AKT restores apoptotic sensitivity in various cancers to diverse chemotherapeutic agents, yet the optimal mechanism of inhibition of AKT has yet to be clearly defined. Pancreatic cancer is one of the most difficult to treat given its extreme resistance to the cytotoxic effect of traditional therapy; investigations into therapies to restore apoptotic sensitivity have identified AKT as a potenial target for inhibition. The evolving targeted inhibition of AKT, whether directly or indirectly, is an active area of research with tremendous potential in cancer therapy, and pancreatic cancer specifically, and this field of research is discussed in the current review.",
keywords = "Akt, Apoptosis, Autophagy, NF-κB, Pancreatic cancer",
author = "Bowles, {Tawnya L.} and Colin Parsons and Muilenburg, {Diego J.} and Bold, {Richard J}",
year = "2009",
doi = "10.2174/157339409789712654",
language = "English (US)",
volume = "5",
pages = "288--295",
journal = "Current Cancer Therapy Reviews",
issn = "1573-3947",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Targeted inhibition of AKT in pancreatic cancer

AU - Bowles, Tawnya L.

AU - Parsons, Colin

AU - Muilenburg, Diego J.

AU - Bold, Richard J

PY - 2009

Y1 - 2009

N2 - The understanding of the barriers to effective treatment of cancer is rapidly expanding. As the molecular pathways of apoptosis become better understood, the mechanisms by which cancer cells evade the apoptotic effect of standard chemotherapeutic agents are revealed. Protein kinase B/AKT mediates a potent survival/anti-apoptotic signal when activated; many cancers have been observed to harbor constitutive activation. The mechanism of constitutive activation of AKT in cancer is not usually due to mutation or amplification of the gene, but through activation of upstream signaling events. Extensive preliminary data has shown that inhibition of AKT restores apoptotic sensitivity in various cancers to diverse chemotherapeutic agents, yet the optimal mechanism of inhibition of AKT has yet to be clearly defined. Pancreatic cancer is one of the most difficult to treat given its extreme resistance to the cytotoxic effect of traditional therapy; investigations into therapies to restore apoptotic sensitivity have identified AKT as a potenial target for inhibition. The evolving targeted inhibition of AKT, whether directly or indirectly, is an active area of research with tremendous potential in cancer therapy, and pancreatic cancer specifically, and this field of research is discussed in the current review.

AB - The understanding of the barriers to effective treatment of cancer is rapidly expanding. As the molecular pathways of apoptosis become better understood, the mechanisms by which cancer cells evade the apoptotic effect of standard chemotherapeutic agents are revealed. Protein kinase B/AKT mediates a potent survival/anti-apoptotic signal when activated; many cancers have been observed to harbor constitutive activation. The mechanism of constitutive activation of AKT in cancer is not usually due to mutation or amplification of the gene, but through activation of upstream signaling events. Extensive preliminary data has shown that inhibition of AKT restores apoptotic sensitivity in various cancers to diverse chemotherapeutic agents, yet the optimal mechanism of inhibition of AKT has yet to be clearly defined. Pancreatic cancer is one of the most difficult to treat given its extreme resistance to the cytotoxic effect of traditional therapy; investigations into therapies to restore apoptotic sensitivity have identified AKT as a potenial target for inhibition. The evolving targeted inhibition of AKT, whether directly or indirectly, is an active area of research with tremendous potential in cancer therapy, and pancreatic cancer specifically, and this field of research is discussed in the current review.

KW - Akt

KW - Apoptosis

KW - Autophagy

KW - NF-κB

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=71749088786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71749088786&partnerID=8YFLogxK

U2 - 10.2174/157339409789712654

DO - 10.2174/157339409789712654

M3 - Article

AN - SCOPUS:71749088786

VL - 5

SP - 288

EP - 295

JO - Current Cancer Therapy Reviews

JF - Current Cancer Therapy Reviews

SN - 1573-3947

IS - 4

ER -